Skip to main content
丹娜生物 logo

丹娜生物 — Investor Relations & Filings

Ticker · 920009 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 61 across all filing types
Latest filing 2026-05-07 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920009

About 丹娜生物

https://www.dynamiker.com/

Dynamiker Biotechnology specializes in the research, development, and manufacturing of in vitro diagnostic (IVD) solutions, focusing on the early detection and monitoring of invasive fungal diseases (IFD). The company offers a comprehensive diagnostic portfolio targeting pathogens such as Aspergillus, Candida, Cryptococcus, and Pneumocystis jirovecii. Its core product lines include (1-3)-β-D-glucan (G test), Galactomannan (GM test), and Cryptococcal Antigen (CrAg) assays, utilizing methodologies like ELISA, lateral flow, and molecular diagnostics. These products are designed to provide rapid, sensitive, and specific results for clinical decision-making. Dynamiker maintains international quality standards and certifications, supporting its commitment to improving diagnostic accuracy and patient management in global healthcare settings.

Recent filings

Filing Released Lang Actions
对外投资公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding an external investment made by the company through its wholly owned subsidiary establishing a new subsidiary in Singapore. It explicitly states that the investment does not constitute a major asset restructuring or related party transaction, and it details the investment amount, decision-making process, and risk assessment. The document is relatively short (1486 characters) and serves as a formal disclosure of the investment event rather than a detailed financial report or management discussion. There is no indication of financial statements, audit opinions, or detailed financial analysis. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about a corporate action that does not fit into more specific categories like Capital/Financing Update or M&A Activity. Therefore, the appropriate classification is Regulatory Filings (RNS).
2026-05-07 Chinese
招商证券股份有限公司关于丹娜（天津）生物科技股份有限公司预计2026年日常性关联交易的专项核查意见
Regulatory Filings
2026-04-07 Chinese
募集资金年度存放、管理与使用情况鉴证报告
Regulatory Filings
2026-04-07 Chinese
非经营性资金占用及其他关联资金往来情况专项说明
Audit Report / Information Classification · 85% confidence The document is issued by an accounting firm (RSM China) as a special explanation (“专项说明”) on non-operating fund occupancy and related-party fund dealings for the 2025 year. It references the firm’s audit opinion and includes detailed audited schedules. This is not a full annual or interim report but a standalone audit‐related explanatory statement. Therefore, it falls under Audit Report / Information (AR). FY 2025
2026-04-07 Chinese
2025年年度报告业绩说明会预告公告
Investor Presentation Classification · 95% confidence The document is a notice announcing a scheduled performance explanation meeting (业绩说明会) related to the company's 2025 Annual Report. It references the actual 2025 Annual Report and its summary, which were disclosed earlier, but this document itself is not the report. The document is short (1061 characters) and serves as an announcement for the upcoming investor meeting to discuss the annual results, not the full report or detailed financial data. Therefore, it fits the category of an Investor Presentation (IP) or possibly an Announcement related to the Annual Report. However, since it is specifically about an '业绩说明会' (performance explanation meeting), which is a detailed presentation for investors focusing on financials and strategy, the best classification is Investor Presentation (IP).
2026-04-07 Chinese
2025年度董事会工作报告
Board/Management Information Classification · 95% confidence The document is titled '2025 年度董事会工作报告' which translates to '2025 Annual Board Work Report'. It details the board's activities, company performance, governance, and future plans for the year 2025. It includes operational results, board meeting frequency, committee activities, and compliance with laws and regulations. The document is a comprehensive report on the board's work rather than a simple announcement or a financial statement. It does not contain detailed financial statements or quarterly data, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a proxy statement, voting results, or remuneration report. The focus is on the board's activities and governance over the year, which fits the category of Board/Management Information (MANG). The document length is 3409 characters, which is relatively short but contains substantive content about board operations and company governance. Therefore, the best classification is MANG with high confidence.
2026-04-07 Chinese

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.